Servier

    OverviewSuggest Edit

    Servier is a research-based group dedicated to health care. As the top-ranked French independent pharmaceutical laboratory, Servier reinvests more than 25% of its turnover in Research and Development. As a result, there are currently 29 new drug candidates under development in the following therapeutic areas: cardiology, oncology, metabolism, neuropsychiatry and rheumatology. With a presence on 5 continents and in 146 countries, Servier has put a total of 867 million drug treatments in the hands of patients in 2014. 92% of Servier's medicines are prescribed internationally.
    TypePrivate
    Founded1954
    HQSuresnes, FR
    Websiteservier.com
    Employee Ratings4

    Latest Updates

    Employees (est.) (Sept 2021)11,371
    Job Openings2
    Cybersecurity ratingCMore

    Servier Office Locations

    Servier has offices in Suresnes, Pittsburg, Tulsa, Panama City and in 62 other locations
    Suresnes, FR (HQ)
    50 Rue Carnot
    Sidi M'Hamed, DZ
    Algiers
    Minsk, BY
    303, vulica Miasnikova 70
    Varna, BG
    bul. "Tsar Osvoboditel" 14, ет.4София
    Laval, CA
    235 Boulevard Armand - Frappier
    Toronto, CA
    161 Bay St Suite 2410 (24th floor
    Show all (79)

    Servier Financials and Metrics

    Summary Metrics

    Founding Date

    1954

    Servier Cybersecurity Score

    Cybersecurity ratingPremium dataset

    C

    78/100

    SecurityScorecard logo

    Servier Online and Social Media Presence

    Embed Graph

    Servier News and Updates

    Servier and OSE Immunotherapeutics Announce Enrollment of First Patient in OSE-127/S95011 Phase 2 Clinical Trial in Sjögren’s Syndrome

    PARIS and NANTES, France, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE), a French biotech, have announced enrollment of the first patient in the Phase 2 clinical trial of OSE-127/S95011 in Sjögr…

    Servier Announces Positive Topline Data from the Global Phase 3 Study of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

    PARIS and BOSTON, Aug. 2, 2021 /PRNewswire/ -- Servier, a global pharmaceutical company, today announced the global Phase 3 double blinded placebo controlled AGILE study of TIBSOVO (ivosidenib tablets) in combination with the chemotherapy azacitidine in adults with previously untreated...

    Servier and Nymirum Announce Strategic Collaboration to Discover and Develop RNA-Targeted Small Molecule Therapeutics

    PARIS, July 12, 2021 /CNW/ -- Servier, a global independent pharmaceutical Group, and Nymirum, a pioneer in RNA-targeted small molecules, announced today that they have entered into a strategic collaboration to identify and develop RNA-modulatory drugs for the treatment of neurological...

    Servier Announces Promising Phase 1 Data for Vorasidenib in IDH Mutant Low-Grade Glioma Published in Clinical Cancer Research

    BOSTON, June 16, 2021 /PRNewswire/ -- Servier, a growing leader in oncology committed to bringing the promise of tomorrow to the patients we serve, today announced that Clinical Cancer Research has published data from its Phase 1 study evaluating single-agent vorasidenib in isocitrate...

    Servier and PRISM BioLab enter drug discovery collaboration for a novel target

    PRISM BioLab provides PepMetics™ (peptide mimetic small molecules) Technology for generating Hit and Lead compounds against Servier’s novel target.read more

    Servier and Oncodesign announce the selection of a preclinical candidate as part of their collaboration targeting new treatments for Parkinsons disease

    Second milestone reached: selection of a LRRK2 kinase inhibitor preclinical candidate Oncodesign receives a €2 million milestone payment, the partnership agreement providing for up to €320 million in milestone payments, excluding sales royalties Regulatory…
    Show more

    Servier Blogs

    MyFood: two brochures available for patients and health care professionals

    […] L’article MyFood: two brochures available for patients and health care professionals est apparu en premier sur Servier.

    In September, Servier is supporting Childhood and Blood Cancer Awareness Month!

    […] L’article In September, Servier is supporting Childhood and Blood Cancer Awareness Month! est apparu en premier sur Servier.

    Launch of Let’s Volunteer by Mécénat Servier!

    […] L’article Launch of Let’s Volunteer by Mécénat Servier! est apparu en premier sur Servier.

    #BecauseIsayso #TakeYourMedicine: new edition of the hypertension awareness campaign

    […] L’article #BecauseIsayso #TakeYourMedicine: new edition of the hypertension awareness campaign est apparu en premier sur Servier.

    Parkinson: a collaboration for the benefit of therapeutic acceleration

    […] L’article Parkinson: a collaboration for the benefit of therapeutic acceleration est apparu en premier sur Servier.

    Servier, 2nd sponsor of the ESC 2021 Congress!

    […] L’article Servier, 2nd sponsor of the ESC 2021 Congress! est apparu en premier sur Servier.
    Show more

    Servier Frequently Asked Questions

    • When was Servier founded?

      Servier was founded in 1954.

    • How many employees does Servier have?

      Servier has 11,371 employees.

    • Who are Servier competitors?

      Competitors of Servier include Pierre Fabre, Merz North America and Laboratorios Bago.

    • Where is Servier headquarters?

      Servier headquarters is located at 50 Rue Carnot, Suresnes.

    • Where are Servier offices?

      Servier has offices in Suresnes, Pittsburg, Tulsa, Panama City and in 62 other locations.

    • How many offices does Servier have?

      Servier has 79 offices.